

Curriculum Vitae

Name : **陳 建 綸** Chien-Lun Chen, M.D., Ph.D.

Education : (Date, Name of Medical or Dental School, Location)

<u>DEGREE</u>	<u>YEAR</u>	<u>INSTITUTION</u>	<u>DISCIPLINE</u>
M. D.	1994	Kaoushing Medical College, Taiwan	Medicine
Resident	1994-1995	Chang Gung Hospital, Taiwan	Surgery
	1996-2000	Chang Gung Hospital, Taiwan	Urology
Ph. D.	2000-2007	Graduate Institute, Clinical Medical Science , Chang Gung University, Taiwan	Science
Fellow	2002-2004	Johns Hopkins Hospital, USA	Urology
Attending	2000 ~	Chang Gung Memorial Hospital, Taiwan	Urology
Director	2010 ~2016	Chang Gung Memorial Hospital, Taiwan	Geriatric Urology
Assist. Prof.	2008~2014	Chang Gung University	
Assoc. Prof.	2015~present	Chang Gung University	

Professional Affiliations : (Medical Organizations or Societies)

台灣外科醫學會會員
台灣泌尿腫瘤醫學會會員
台灣男性學醫學會會員
台灣雷射光電醫學會會員
台灣泌尿科醫學會會員(TUA)
美國泌尿科醫學會會員(AUA)
歐洲泌尿科醫學會會員(EAU)
國際泌尿科醫學會會員(SIU)

Academic and Administrative Experience

擔任林口長庚醫院高齡泌尿科主任 (2010~2016)
教育部部定副教授 (2015~)
長庚大學醫學院兼任副教授 (2015~)
林口長庚紀念醫院最優教師 (102 年度)

Bibliography :

A. Publications :

- 1.**Chen CL**, Huang ST, Chang PL, Ng KF. Adrenal ganglioneuroma: report of five cases. Chang Gung medical journal. 2000;23(9):550-554.
- 2.**Chen CL**, Sung J, Cohen M, et al. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. The Journal of pharmacology and experimental therapeutics. 2006;319(2):533-542.
- 3.Lee SH, Chang PL, Chen SM, **Chen CL** et al. Synchronous primary carcinomas of the bladder and prostate. Asian journal of andrology. 2006;8(3):357-359.

4. Shen BY, Chang PL, Lee SH, **Chen CL**, Tsui KH. Complications following combined transrectal ultrasound-guided prostate needle biopsies and transurethral resection of the prostate. *Archives of andrology*. 2006;52(2):123-127.
5. Xia Q, Sung J, Chowdhury W, **Chen CL** et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. *Cancer research*. 2006;66(14):7237-7244.
6. **Chen CL**, Tsui KH, Lin CY, Chang PL, Tang P, Yung BY. Can probability of genetic mutation be an indicator of clinical relevance? *Genomics* 2007;90(6):746-750.
7. Hoti N, Li Y, **Chen CL**, et al. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. *Molecular therapy: the journal of the American Society of Gene Therapy*. 2007; 15(8):1495-1503.
8. Tsui KH, Chen SM, Wang TM, **Chen CL** et al. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. *Asian journal of andrology*. 2007;9(5):711-715.
9. Hsu YC, Tsui KH, **Chen CL**, Lee SH, Wu YS, Chang PL. Web-based clinical pathway for reducing practice variations in radical prostatectomy. *Chang Gung medical journal* 2008;31(6):567-575.
10. Tsui KH, Juang HH, Lee TH, Chang PL, **Chen CL**, Yung BY. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. *Acta pharmacologica Sinica* 2008;29(3):364-370.
11. Lee SH, Chen SM, Ho CR, Chang PL, **Chen CL**, Tsui KH. Risk factors associated with transrectal ultrasound guided prostate needle biopsy in patients with prostate cancer. *Chang Gung medical journal*. 2009; 32(6):623-627.
12. Chen YT, **Chen CL**, Chen HW, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. *J Proteome Res*. 2010;9(11):5803-5815.
13. Hou CP, Chang PL, **Chen CL**, Lin YH, Tsui KH. Does adequate bladder cuff excision impact outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. *Chang Gung medical journal*. 2011; 34(5):496-505.
14. Lin YH, **Chen CL**, Hou CP, Chang PL, Tsui KH. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. *Acta pharmacologica Sinica*. 2011; 32(4):537-542.
15. **Chen CL**, Lai YF, Tang P, et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. *J Proteome Res*. 2012;11(12):5611-5629.
16. Chen YT, Chen HW, Domanski D, **Chen CL** et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. *Journal of proteomics* 2012.
17. **Chen CL**, Lin TS, Tsai CH, et al. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. *Journal of proteomics* 2013;85:28-43.

- 18.Hou CP, Chen TY, Chang CC, **Chen CL** et al. Use of the SF-36 quality of life scale to assess the effect of pelvic floor muscle exercise on aging males who received transurethral prostate surgery. *Clinical interventions in aging* 2013;8:667-673.
- 19.Hou CP, Lin YH, **Chen CL**, Chang PL, Tsui KH. Clinical outcome of primary small cell carcinoma of the urinary bladder. *OncoTargets and therapy* 2013;6:1179-1185.
- 20.Lee WC, Lin YH, Hou CP, **Chen CL** et al. Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging males. *Clinical interventions in aging* 2013;8:1483-1488.
- 21.Lin YH, Chen YJ, Lai CS, **Chen CL** et al. A negative-pressure-driven microfluidic chip for the rapid detection of a bladder cancer biomarker in urine using bead-based enzyme-linked immunosorbent assay, *Biomicrofluidics* 2013;7(2):24103.
- 22.Shao IH, Hou CP, Chen SM, **Chen CL** et al. The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia. *Clinical interventions in aging* 2013;8:265-269.
- 23.Chen HC, Chen YT, Tsai RY, **Chen CL** et al. A sensitive and selective magnetic graphene composite-modified polycrystalline-silicon nanowire field-effect transistor for bladder cancer diagnosis, *Biosensors & bioelectronics* 2014; 66c:198-207.
- 24.Chung PJ, Chi LM, **Chen CL**, et al. MicroRNA-205 targets tight junction-related proteins during urothelial cellular differentiation. *Molecular & cellular proteomics: MCP*. 2014; 13(9):2321-2336.
- 25.Hou CP, **Chen CL**, Lin YH, et al. Prostatic urethral angle might be a predictor of treatment efficacy of alpha-blockers in men with lower urinary tract symptoms. *Drug design, development and therapy* 2014; 8:937-943.
- 26.Juo CG, **Chen CL**, Lin ST, et al. Mass accuracy improvement of reversed-phase liquid chromatography/electrospray ionization mass spectrometry based urinary metabolomic analysis by post-run calibration using sodium formate cluster ions. *Rapid communications in mass spectrometry: RCM*. 2014; 28(16):1813-1820.
- 27.Peng J, Chen YT, **Chen CL**, Li L. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery. *Analytical chemistry* 2014;86(13):6540-6547.
- 28.Shao IH, Lin YH, Hou CP, **Chen CL** et al. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. *Drug design, development and therapy* 2014; 8:1985-1990
- 29.Yang PS, Hsu YC, Lin YH, **Chen CL** et al. The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis. *OncoTargets and therapy* 2014; 7:1777-1781
- 30.**Chen CL**, Chung T, Wu CC, et al. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer. *Molecular & cellular proteomics: MCP*. 2015; 14(9):2466-2478.

31. Hou CP, Lee WC, Lin YH, **Chen CL** et al. Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer. *OncoTargets and therapy* 2015; 8:15-19.
32. Hou CP, Lin YH, Hsieh MC, **Chen CL** et al. Identifying the variables associated with pain during transrectal ultrasonography of the prostate. *Patient Prefer Adherence*. 2015; 9:1207-1212.
33. Hou CP, Lin YH, Hsu YC, **Chen CL**, Chang PL, Tsui KH. Using a Harmonic Scalpel "Drilling and Clamping" Method to Implement Zero Ischemic Robotic-assisted Partial Nephrectomy: An Observation Case Report Study. *Medicine (Baltimore)* 2016; 95 (3):e2349.
34. Hsu YC, Lin YH, Chou CY, **Chen CL** et al. Economic Evaluation Study (Cheer Compliant) Laser Prostatectomy for Benign Prostatic Hyperplasia: Outcomes and Cost-effectiveness. *Medicine (Baltimore)* 2016; 95 (5):e2644.
35. Shao CH, **Chen CL**, Lin JY, et al. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. *Oncotarget* 2017; 8(24):38802-38810.
36. Lin YH, Hou CP, Chen TH, **Chen CL**, et al. Is diabetes mellitus associated with clinical outcomes in aging males treated with transurethral resection of prostate for bladder outlet obstruction: implications from Taiwan Nationwide Population-Based Cohort Study. *Clin Interv Aging* 2017;12:535-541.
37. Kan HC, Hou CP, Lin YH, Tsui KH, Chang PL, **Chen CL***(**Coresponding**). Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis. *OncoTargets and therapy*. 2017; 10: 2943-2949.
38. Hou CP, Lin YH, Chen TH, **Chen CL**, et al. Transurethral resection of the prostate achieves favorable outcomes in stroke patients with symptomatic benign prostate hyperplasia. *The aging male: the official journal of the International Society for the Study of the Aging Male*. 2017:1-8.
39. Lin YH, Hou CP, Chen TH, **Chen CL**, et al. Transurethral resection of the prostate provides more favorable clinical outcomes compared with conservative medical treatment in patients with urinary retention caused by benign prostatic obstruction. *BMC geriatrics*. 2018;18(1):15.
40. Yang PS, **Chen CL**, Hou CP, Lin YH, Tsui KH. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin. *Clin Interv Aging*. 2018 Feb 8;13:235-242. doi: 10.2147/CIA.S152701. eCollection 2018.
41. Hou CP, Lin YH, **Chen CL**, et al. Transurethral resection of the prostate achieves favorable outcomes in stroke patients with symptomatic benign prostate hyperplasia. *The aging male : the official journal of the International Society for the Study of the Aging Male* 2018, 21 (1), 9-16.
42. Tsai, CH; Chen, YT; Chang, YH; Hsueh, C; Liu, CY; Chang, YS; **Chen CL***(**Coresponding**)., et al. Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens. *Oncotarget* 2018, 9 (56), 30731-30747.
43. Chen, Y.-T.; Huang, H.-C.; Hsieh, Y.-J.; Fu, S.-H.; Li, L.; **Chen CL**, et al. Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for

- evaluation of bladder cancer biomarkers. *Journal of food and drug analysis* 2019, 27 (2), 460-474.
44. Chen, Y.-T.; Ou Yang, W.-T.; Juang, H.-H.; **Chen CL*(Corresponding)**, et al. Proteomic characterization of arsenic and cadmium exposure in bladder cells. *Rapid communications in mass spectrometry : RCM* 2019, e8578-e8578.
45. Chen, Y.-T.; Tsai, C.-H.; **Chen CL**, et al, Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. *Journal of food and drug analysis* 2019, 27 (2), 387-403.
46. Chen, Y. T.; Huang, H. C.; Hsieh, Y. J.; Fu, S. H.; Li, L.; **Chen CL**, et al., Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. *Journal of food and drug analysis* 2019, 27 (2), 460-474.
47. Chen, Y. T.; Tsai, C. H.; **Chen CL**, et al., Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. *Journal of food and drug analysis* 2019, 27 (2), 387-403.
48. Lin, Y.-H.; Hou, C.-P.; Juang, H.-H.; Chang, P.-L.; Chen, T.-H.; **Chen CL**, et al., Association between Bladder Outlet Obstruction and Bladder Cancer in Patients with Aging Male. *J Clin Med* 2019, 8 (10), 1550.
49. Hou, C.-P.; Lin, Y.-H.; Juang, H.-H.; Chang, P.-L.; **Chen CL**, et al., Clinical outcome of transurethral enucleation of the prostate using the 120-W thulium Laser (Vela™ XL) compared to bipolar transurethral resection of the prostate (TURP) in aging male. *Aging* 2020, 12 (2), 1888-1898.

B. Book Chapters

1. **Chien-Lun Chen** Doctoral thesis: Beyond Sequence Fidelity – Roles of Population Genetics and Epigenetics in Bladder Cancer Genome and Our Treatment Strategy. Jan. 2008. Graduate Institute, Clinical Medical Science, Chang Gung University, Taiwan
2. Yi-Ting Chen, Carol E. Parker, Hsiao-Wei Chen, **Chien-Lun Chen**, Dominik Domanski, Derek S. Smith, Chih-Ching Wu, Ting Chung, Kung-Hao Liang, Min-Chi Chen, Yu-Sun Chang, Christoph H. Borchers, and Jau-Song Yu. "A Pipeline that Integrates the Discovery and Verification Studies of Urinary Protein Biomarkers Reveals Candidate Markers for Bladder Cancer". *Royal Society of Chemistry (RSC) 2013*, **0**, 271-314. **ISBN: 978-1-84973-422-6**.